ArticleToxins2024
Trimethylamine N-Oxide (TMAO) Plasma Levels in Patients with Different Stages of Chronic Kidney Disease.
Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- First Hydration Shell Integrity: Key to Protein Stability.Journal of the American Chemical Society · 2026Article
- Trimethylamine N-oxide and Homocysteine in Kidney Function and Disease: Distinct Metabolic Origins, Shared Renal Determinants and Pathophysiological Pathways.International journal of molecular sciences · 2026Review
- Review
- Serum metabolomics identifies gut-derived uremic toxins and bile acid dysregulation associated with chronic kidney disease severity.Scientific reports · 2026Article
- Gut Microbiota-Derived Trimethylamine N-Oxide and NT-proBNP in Heart Failure: A Critical Review of Diagnostic and Prognostic Value.Biomedicines · 2026Review
- Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease.Biomedicines · 2026Review
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
- Fucoidan Therapy for Extraintestinal Diseases: Targeting the Microbiota-Gut-Organ Axes.Biomolecules · 2025Review
- Advancements in the non-invasive diagnosis of renal fibrosis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with chronic kidney disease (CKD), trimethylamine n-oxide (TMAO) accumulation exacerbates inflammation and contributes to oxidative stress. These complications are putatively linked to the development of cardiovascular diseases. Despite the known associations, the variation in TMAO plasma levels across different CKD stages and dialysis modalities remains underexplored. This study aimed to quantify TMAO plasma levels in different CKD stages and dialysis treatments.
methodsThis cross-sectional study assessed TMAO plasma levels in non-dialysis CKD patients (ND), patients undergoing hemodialysis (HD), and peritoneal dialysis (PD). TMAO plasma levels were assessed by liquid chromatography coupled to triple mass spectrometry quadrupole.
resultsIn total, 15 ND patients [stages 3-5, glomerular filtration rate 41.4 mL/min/1.73 m
conclusionsCKD stages impact TMAO levels since patients on non-dialysis treatment had lower levels than patients on HD and PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.